Press Room

2007 Press Releases

TSX:V - IXS
NASD OTC:BB: IXSBF

November 03, 2007

InNexus Biotechnology Hosts Company Operational Update Teleconference in New York City

British Columbia, Canada - November 2, 2007 - InNexus Biotechnology Inc. (OTCBB: IXSBF) (TSX VENTURE: IXS), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, will host an operational update teleconference on November 8th at 11:00 AM ET to discuss fiscal year 2007 and ongoing operations including the pre-clinical program of its lead product, DXL625 (CD20). Participants can listen to the teleconference by logging onto: http://www.vcall.com/IC/CEPage.asp?ID=122645 or dialing 866-585-6398. International callers can dial in using 416-849-9626. A playback of the teleconference will be available using the replay number 866–245–6755 and international callers can call using 416-915-1035 pass code 864013 or log onto http://www.vcall.com/IC/CEPage.asp?ID=122645. The playback will be available for seven days after the live teleconference.

About InNexus

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL™ technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL™ antibodies utilize unique, novel and patented methods and technologies of InNexus.

InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit www.ixsbio.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward–looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, that may cause actual results or performance to differ materially from those currently anticipated in such statements.

Contact

InNexus Biotechnology Inc.
Wade Brooksby, CFO
480-862-7500

The Investor Relations Group
Investor Relations:
Christine Berni/Joe Triunfo, 212-825-3210
cberni@investorrelationsgroup.com
jtriunfo@investorrelationsgroup.com
Media:
Janet Vasquez/ Michaela Heller, 212-825-3210
jvasquez@investorrelationsgroup.com
mheller@investorrelationsgroup.com